Table 5.
Crude and adjusted all-cause and CVD-related mortality according to testosterone levels in 126 prevalent HD mena
| Model | Covariates | All-Cause Mortality
|
CVD Mortality
|
||
|---|---|---|---|---|---|
| HR (95% CI) | P Value | HR (95% CI) | P Value | ||
| 1 | Crude | 2.03 (1.24 to 3.31) | 0.004 | 3.19 (1.49 to 6.83) | 0.002 |
| 2 | 1 + age and SHBG | 1.94 (1.16 to 3.26) | 0.01 | 2.96 (1.32 to 6.61) | 0.008 |
| 3 | 2 + baseline CVD, diabetes mellitus, and ACEI/ARB medication | 2.21 (1.28 to 3.82) | 0.004 | 2.79 (1.21 to 6.48) | 0.01 |
| 4 | 3 + IL-6 | 1.77 (1.06 to 3.70) | 0.03 | 2.53 (1.07 to 5.99) | 0.03 |
| 5 | 4 + s-albumin | 1.74 (1.01 to 3.02) | 0.04 | 2.47 (1.04 to 5.87) | 0.04 |
| 6 | 5 + s-creatinine | 1.51 (0.86 to 2.72) | 0.14 | 2.00 (0.80 to 4.95) | 0.13 |
a
Indicated are HRs for all-cause and CVD mortality for patients with testosterone concentration below the 33rd percentile of testosterone distribution crude (model 1) or with various degrees of adjustment (models 2 to 6).